A Study of Mirikizumab (LY3074828) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2015

Primary Completion Date

July 16, 2018

Study Completion Date

October 24, 2018

Conditions

Healthy

Interventions

DRUG

Mirikizumab - IV

Administered IV

DRUG

Mirikizumab - SC

Administered SC

DRUG

Placebo - IV

Administered IV

DRUG

Placebo - SC

Administered SC

Trial Locations (1)

WCCT Global, Cypress

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT02568423 - A Study of Mirikizumab (LY3074828) in Healthy Participants | Biotech Hunter | Biotech Hunter